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Abstract Monoclonal antibodies were raised that specifically recognize the COOH-terminal sequences and the loop sequences between the fifth and 
the sixth transmembrane spanning regions of human inositol1,4,5-trisphosphate r ceptor (IP,R) type 1,2 and 3. Western blot analysis using Jurkat 
cells, mouse cerebellum, COS-7 expressing IP,R type 3 cDNA showed that those monoclonal antibodies reacted specifically with each of these three 
IP,R subtypes and that they do not cross-react. These antibodies could be used for the specific immunoprecipitation of IP,Rs. Using these monoclonal 
antibodies, the expression profiles of IP,R-subtype proteins were found to be different among inflammatory cells such as macrophages, polymor- 
phonuclear cells, mast cells, eosinophils, splenocytes, thymocytes and megakaryocytic cells. Usually, more than one type of IP,R were expressed in 
a cell simultaneously. The observation of CMK cells under immunofluorescence onfocal microscopy revealed that IP,R type 1 and type 2 are located 
at different subcellular fractions. 
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1. Introduction 
Phosphatidyl inositol 4,5-bisphosphate is hydrolyzed in re- 
sponse to receptor stimulation on the plasma membrane to 
produce inositol 1,4,5_trisphosphate (IP,) and diacylglycerol. 
IP, is a physiological ligand known to mediate internal Ca’+ 
release from intracellular Ca” storage sites by binding to its 
specific receptor named the IP, receptor (IP,R) [l]. The IP,R 
in cerebellar Purkinje cells forms a tetramer in order to function 
as a Ca” channel [2,3]. This signal transduction system is used 
in cells of diverse types and is an essential process leading to 
specific cellular responses [4]. Recently, proteins immunoreac- 
tive to anti-IP,R antibodies or IP,-gated Ca*’ channels have 
been reported to exist on the plasma membranes of T cells, 
B cells, olfactory neurons and endothelial cells [5--g]. 
The IP,R encoded in the first cloned mouse IP,R cDNA 
from cerebellar Purkinje cells is now termed IP,R type 1 [lo], 
since recent molecular cloning studies, including our own stud- 
ies on human receptors, have revealed that there is a family of 
IP,Rs. The full-length cDNAs for IP3R subtypes, termed IP,R 
type 2 and type 3, have been isolated [l l-151. The presence of 
another type of IP,R, type 4, is also suggested [16]. Our North- 
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Abbreviations: IP,, inositol 1,4,5_trisphosphate; IP,R, IP, receptor; 
ELISA, enzyme linked immunosorbent assay; PMN, polymorphonu- 
clear cell; SD rat, Sprague+Dawley rat; FITC, fluorescein isothiocya- 
nate. 
ern and dot blot analyses of human hematopoietic ell lines 
using the subtype-speciftc cDNA regions of these human IP,Rs 
as probes revealed that each IP,R subtype is differently ex- 
pressed in these cells and that most of cells studied express at 
least two distinct types of IP,R simultaneously. Moreover, it 
was proved that the xpression profile of these subtypes in each 
cell changed dynamically in response to stimuli which induce 
cell differentiation [17]. These findings prompted us to investi- 
gate the difference in functions, and tissue/cellular and subcel- 
lular localization of these IP,R subtypes. Immunohistochemi- 
cal studies using the monoclonal antibodies raised against IP,R 
type 1 have shown that whilst the subtype is distributed in many 
areas of the brain, its expression is especially high in the Purk- 
inje cells [18]. However, to date, such studies for IP3R type 2 
and type 3 are rather limited [11,12,14] essentially because of 
the lack of monoclonal antibodies specific to each of IP,R 
subtypes, especially those to IP,R type 2 and type 3. Such a set 
of monoclonal antibodies could also be a great help for the 
analysis of the subunit composition of the Ca2’ channels to 
examine if they are homotetramer or heterotetramer. 
In spite of their high level identities [13-l 51, the cloning and 
the sequencing analysis of the three subtypes of human IP,R 
cDNA enabled us to find several subtype-specific regions 
[ 13,151. In this study, we have established the monoclonal anti- 
bodies specific to each of the three IP,R subtypes using the 
synthetic peptides corresponding to the loop region between 
the fifth and the sixth transmembrane regions and to the 
COOH-terminal regions. Employing these monoclonal anti- 
bodies, we have analyzed the expression of the IP3R subtypes 
in inflammation-related blood cells, and have found that each 
member of the IP,R family is expressed ifferently among those 
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cell types as well as being localized at different subcellular 
compartments. 
2. Materials and methods 
2.1. Cells and cell culture 
A human T cell line (Jurkat) and a megakaryocytic CMK cell line 
were maintained as described [17]. COS-7 and COS-7 expressing human 
IP,R type 3 were grown according to Hino et al [13]. Cerebellum was 
obtained from ICR mouse. Macrophages and polymotphonuclear cells 
(PMN) were harvested from the peritoneal cavities of SpragueDawley 
(SD) rats after intraperitoneal injection of thioglycollate broth [19] and 
casein [20], respectively. Mast cells from the same cavity of SD rat 
were purified using Ficoll400 (,Pharmacia LKB Biotechnology, Swe- 
den) [21]. Splenocyte and thymocyte suspensions from SD rats were 
prepared as described [22,23]. Eosinophils were harvested from the 
peritoneal cavities of Hartley guinea pig after intraperitoneal injection 
of normal horse serum [24]. The purity of these cells prepared from rats 
and guinea pigs were more than 90%. 
2.2. Preparation of peptide antigens 
Peptides were synthesized using standard Fmoc (9-fluorenyl- 
methoxycarbonyl) method on a peptide synthesizer PSSMI (Simadzu, 
Japan). The synthesized peptides corresponding to the IP,R CQGH- 
terminal regions were CLGHPPHMNVNPQQPA (peptide-lC, amino 
acid residues 2.681-2.695). CLGSNTPHVNHHMPPH (nentide-2C. 
2,687-2,701) and CRQRLGFVDVQNS*ISR (peptide-26, 2,657- 
2,671) for IP,R type 1, type 2 and type 3, respectively. The peptides 
corresponding to the IP,R loop region between the 6fth and the sixth 
transmembrane r gions were CGESLANDFLYSDVS*R (peptide-lL, 
2,483-2,497), CGSHQVPTMTLTTMME (peptide-ZL, %43‘6-2,450) 
and CSPLGMPHGAAAFVDT (nentide-3L. 2.410-2.424) for IP,R 
type 1, type 2 and type 3, respect&eiy. Se&s designated as S* were 
introduced instead of the original cysteins to avoid disuhide bond 
formation. Cysteins were attached to all of the peptides as the 
N-terminal spacer amino acids used as the coupling sites for the prep- 
aration of keyhole limpet hemocyanin (KLH; Carbiochem, USA)-pep- 
tide conjugates. 
2.3. Immunization andpreparation of hybridomu 
Procedures for immunization of BALB/c mice with the peptide-KLH 
conjugates, cell fusion and hybridoma selection were as described [25]. 
Aliquots of the culture supematants from each of the hybridomas were 
tested in ELISA for the presence of mouse immunoglobulins with 
specificity directed against the original immunizing antigens. These 
supematants were also tested for antibody activity against the other 
types of IP,R peptides to examine their specificity. 
2.4. Screening of candidate monoclonal ntibodies by ELISA 
The antigens used in the ELISA screening were the thyroglobulin- 
peptide conjugates. The conjugates were coated on 96-well ELISA 
PLATTE (Greiner, Germany) by passive absorption for 16 h at 4OC. 
The mates were washed with nhosnhate-butfered saline (PBS; 0.14 M 
NaCi, 0.01 M sodium phosphate, pH 7.2), and blocked by addition of 
1% BSA in PBS followed by incubation for 1 h at room temperature. 
After washing, the culture supematant of each hybridoma was added 
and incubated for 2 h at room temperature. The plates were washed 
with 0.05% Tween 20 in PBS followed by addition of the peroxidase- 
conjugated rabbit anti-mouse immunoglobulin solution (Dako, Japan), 
and incubated for 1 h at room temperature. After washing, the plates 
were incubated at room temperature with peroxidase substrate (2,2’- 
azino bis-(3-ethylbenzothiazolined-sulfonic acid). The color was quan- 
tified by measuring the absorption at 415 nm on a micro-plate reader 
NJ2001 (Japan Intermed). 
2.5. Determination of immurwglobulin isotypes 
The supematants of the hybridoma cultures were tested as described 
above with the exception of the second antibody. For this purpose, 
peroxidaseconjugated rabbit anti-mouse IgGl, IgG2a, IgG2b and 
IgG3 monoclonal antibodies (Zymed, USA) were used. 
2.6. Membrane preparation and Western blotting 
Cells were homogenized in ice-cold 5 mM Tris-HCl (pH 7.4) contain- 
ing 1 mM EDTA, 0.25 M sucrose, 0.1 mM phenyhnethylsulfonyl fluo- 
ride (PMSF) (Wake Pure Chemical Industries, Ltd., Japan), 10 PM 
Pep&tin A (Peptide Institute. Inc., Japan) and 10pM Leupeptin (Pep- 
tide Institute Inc., Japan), and centrifuged at 2,000 x g for 10 min at 
4’C. The supematants were further centrifuged at 100,000 x g for 30 
min at 4°C. The resultant pellets were resuspended in a solution con- 
taining 50 mM Tris-HCl (PH 7.4), 1 mM EDTA, 0.1 mM PMSF, 10 
PM Pepstatin A and 10pM Leupeptin. The membrane fraction and the 
cells dissolved in the sample buffer (0.1% SDS, 125 mM Tris-HCl, pH 
6.8) were subjected to 6% SDS-PAGE, followed by electroblotting onto 
nitrocellulose sheets (Schleicher and Schuell, Germany). The sheets 
were blocked with skim milk, and further incubated with monoclonal 
antibodies. The monoclonal antibodies tested were those to the CGGH- 
terminal nentide of IP,R Woe 1. KM11 12. to the CCJGH-terminal 
peptide of iP,R type-2, KMld83, KMld84, KM1085, KM1086, 
KM1087 and KMlO89, to the COOH-terminal peptide of IP,R type 3, 
KM1076, KM1077, KM1078, KM1079, KMlO80, KM1081 and 
KMlO82, and to the loop peptide of IP,R type 3, KMl106, KM1 107, 
KM1 108, KM1 109 and KM1 110. As a check for specificity, monoclo- 
nal antibodies preincubated with 10 &ml of their immunized peptides 
were used. The bound monoclonal antibodies were detected using the 
ECL system (Amersham, UK). 
2.7. Immunoprecipitation 
Immunoprecipitation was performed as described [26]. Briefly, mem- 
brane were solubilized in the lysis buffer (50 mM Tris-HCl (pH 7.5), 
1% Triton X-100, 5 mM EDTA, 0.1 mM PMSF, 10pM Pepstatin A, 
10 PM Leupeptin and 1 mM 2-mercaptoethanol) for 30 min at 4°C. 
After centrifugation at 20,000 x g for 30 min at 2”C, the supematants 
were boiled for 5 min in the lysis buffer containing 6 M urea, 20 mM 
dithiothreitol, 1% SDS and 1 % Triton X-100, and dialyzed against 10 
mM sodium phosphate (pH 7.2), 150 mM NaCl, 5 mM EDTA, 0.1 mM 
PMSF, 10 PM Pepstatin A and 10 PM Leupeptin. The solution was 
incubated with 6pg/ml KM1 112, KM1083 and KM1082 for 1 hat 4”C, 
respectively, followed by addition of anti-mouse IgG. The immune 
complexes were collected with Pansorbin (Calbiochem, USA) and sub- 
jected to SDS-PAGE. 
2.8. [3H]IP, binding assay 
Solubilized membranes in the lysis buffer (1% Triton X-100,50 mM 
Tris-HCl (pH 7.5), 5 mM EDTA, 0.1 mM PMSF) were incubated with 
l/20 vol. of normal mouse serum for 1 h at 4’C and then pre-cleared 
with protein G agarose beads (Vivax Biotechnology, USA) for 1 h at 
4°C. The supematant was incubated with 6 &ml KM1083 for 1 h at 
4’C followed by addition of protein G agarose beads and incubated 
further for 1 h at 4°C. The beads were washed with the lysis buffer and 
incubated with 10 nM [‘H]IP, (777 GBq/mmol, NEN/DuPont, USA) 
for 10 min on ice. After centrifugation at 10,000 x g for 5 min, the beads 
were suspended in AQUASOL 2 (NEN/DuPont, USA) and radioactiv- 
ity was analyzed by liquid scintillation counting. 
2.9. Fluorescence confocal microscopy 
Suspensions of CMK cells in PBS were plated onto poly-L-lysine 
coated glass slides and incubated at 37°C for 15 min. The adherent 
CMK cells were tixed in 2% paraformaldehyde, 0.025 M L-lysine and 
0.01 M of periodate in sodium phosphate buffer (pH 6.2) for 15 min 
on ice. After washing with PBS, Zhe &Is were permeabilii with 0.1% 
Triton X-108 in PBS for 10 min at room temwrature followed bv 
blocking with 2% normal horse serum for 30 minat room temperature. 
The cells were incubated with 2 &ml KM1 112 or KM1083 for 16 h 
at 4°C. Normal mouse serum and the monoclonal antibodies preincu- 
bated with 10 &ml of its immunized peptides were used as controls. 
The cells washed with PBS were incubated with biotinylated horse 
anti-mouse immunoglobulin (Vector, USA) for 1 h at room tempera- 
ture. Then the cells were rinsed with PBS and incubated with fluorescein 
isothiocyanate (FITC)-conjugated avidin (Vector, USA). The stained 
cells were examined under fluorescence confocal microscopy using 
In-SIGHT-IQ (Meridian Instruments Far East K.K., Japan). 
3. Results 
3.1. Characterization of monoclonal antibodies 
Mice were immunized with the conjugates containing the 
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Fig. 1. The specificity of the monoclonal antibodies raised against the 
peptides corresponding to the IP,R COOH-terminal regions. Mem- 
brane fraction of Jurkat were subjected to SDS-PAGE (10 pug protein/ 
lane) and Western blotting. The blots were incubated with the monoclo- 
nal antibody KM1112 against peptide-1C for IP,R type 1 (lane l), 
KM1083 against peptide-2C for IP,R type 2 (lane 2), and KM1082 
against peptide-3C for IP3R type 3 (lane 3). The reactions of the mon- 
oclonal antibodies preincubated with each immunizing peptide-1C 
(lane 4), -2C (lane 5) and -3C (lane 6) were also shown. Arrowhead 
indicates the position of IP,Rs. 
COOH-terminal or the loop amino acid sequences of human 
IP,Rs. Preliminary screening by ELISA of the specificities of 
the obtained hybridoma supematants identified a clone de- 
noted KM1 112 recognizing the COGH-terminal peptide of 
IP,R type 1, six clones (denoted KM1083 to KM1087 and 
KM1089, respectively) recognizing the COOH-terminal pep- 
tide of IP,R type 2, seven clones (denoted KM1076 to KM1082, 
respectively) recognizing the COOH-terminal peptide of IP,R 
type 3 and five clones (denoted KM1106 to KMlllO, respec- 
tively) recognizing the loop peptide of IP3R type 3. Hybridomas 
producing antibodies to the loop peptides of IP,R type 1 and 
type 2 were not obtained. These antibodies showed no cross- 
reactivity in ELISA to the peptides other than the immunizing 
antigens (data not shown). The isotype of these antibodies was 
determined to be IgGl with the exception of KM1081 and 
KM1086 (IgG2b) and KM1078, KM1080, KM1083 and 
KM1089 (IgG2a). 
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The specificity of those monoclonal antibodies to each IP,R 
subtype was demonstrated by Western blot analysis using Jur- 
kat cells, mouse cerebellum that expresses IP,R type 1 domi- 
nantly, COS-7 and a recombinant COS-7 expressing IP,R type 
3 cDNA [13]. As shown in Fig. 1, KM1112, KM1083 and 
KM1082 speci&ally reacted with the Jurkat proteins of about 
250 kDa. Staining of the bands was blocked by the immunizing 
peptide-lC, -2C and -3C, respectively. Moreover, the monoclo- 
nal antibodies KM1112, KM1083 and KM1082 reacted only 
with the immunoprecipitated proteins of about 250 kDa with 
KM1 112, KM1083 and KM1082, respectively. No cross-reac- 
tivity was demonstrated (Fig. 2). It was reported that IP,R type 
1 and IP,R type 3 gave specific bands of about 250 kDa on 
SDS-PAGE using an anti-mouse IP,R type 1 monoclonal anti- 
body 4Cll [18] and an anti-IP,R type 3 polyclonal antibody 
[13], respectively. The antibody 4Cll was shown to react with 
the protein with the same migration in this study (data not 
shown). As indicated in Fig. 3, KM1112 specifically reacted 
with a 250 kDa protein of cerebellum and did not react with 
that of COS-7 expressing IPsR type 3. Staining of the band was 
blocked by the immunizing peptide-1C (data not shown). While 
the monoclonal antibodies KM1082 and KM1 109 reacted with 
the 250 kDa protein of COS-7 expressing human IP,R type 3, 
they did not react with that of cerebella. Staining of the band 
was blocked by the immunizing peptide-3C (data not shown). 
These results indicated that our monoclonal antibodies specifi- 
cally recognize IP,R type 1 and type 3. 
As shown in Fig. 3B, the monoclonal antibody KM1083 
recognizes proteins of about 250 kDa which do not react with 
KM 1112, KM 1082 and KM 1109. Since we had no recombinant 
cells expressing IP,R type 2 cDNA, we examined if the protein 
recognized by KM1083 bound IP3. The membrane of Jurkat 
which is known to express IP,R type 2 [17] were solubilized with 
Triton X-100 and immunoprecipitated with KM1083. As 
shown in Fig. 4, the [%IlIP, binding activity was detected in 
KM1083 immunoprecipitates. The result in combination with 
the specific reactivity with the peptide-2C (Fig. 1) and with one 
of the three Jurkat IP,R subtypes other than those of type 1 and 
type 3 (Fig. 2) clearly show that KM1083 recognizes IP,R type 
2 specifically. 
(C> 
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Fig. 2. The specificity of the monoclonal antibodies against each of IP,R subtypes. Solubilized Jurkat membrane proteins were immunoprecipitated 
with the monoclonal antibodies KM1112 (lane l), KM1083 (lane 2) and KM1082 (lane 3). The immunoprecipitates and membrane fraction (lane 
4,10 pug protein/lane) of Jurkat were subjected to SDS-PAGE and Western blotting using KM1 112 (panel A), KM1083 (Panel B), and KM1082 (panel 
C). Arrowhead indicates the position of IP,Rs. 
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Fig. 3. Western blot analysis showing the specificity of the monoclonal antibodies raised against the peptides corresponding to the IP,R COOH- 
terminal regions and the loop regions between the lifth and the sixth transmembrane r gions of IP,Rs. Membrane fractions (2 pg protein/lane) of 
mouse cerebellum (lane 1), COS-7 (lane 2) and COS-7 expressing human IP,R type 3 cDNA (lane 3) were subjected to SDS-PAGE and Western 
blotting using the monoclonal antibodies KM1 112 (panel A), KM1083 (panel B), KM1082 (panel C) and KM1 109 against peptide- for IP,R type 
3 (panel D). Arrowhead indicates the position of IP,Rs. 
Normal 
mouse 
serum 
KM1 083 
Fig. 4. Specific [‘H]IP3 binding of the protein of Jurkat recognized by 
the monoclonal antibody KM1083 raised against peptide-2C for IP,R 
type 2. Jurkat membranes were solubilized and immunoprecipitated 
with KM1083. For control, normal mouse serum was used instead of 
KM1083. Specific [%lIP, binding was measured by liquid scintillation 
All other monoclonal antibodies established also gave 
bands of about 250 kDa on Western blot analysis (data not 
shown). 
3.2. Expression of IP,R subtypes in inflammatory cells 
The expression of IP,R subtype proteins in macrophages, 
PMN, mast cells, splenocytes and thymocytes of rats, and eo- 
sinophils of guinea pigs was examined by Western blot analysis 
using the monoclonal antibodies KM1112, KM1083 and 
KM1082. Those cells were found to express IP,R subtypes of 
about 250 kDa in cell type-specific manner (Fig. 5). Macro- 
phages and PMN predominantly express IP,R type 2. Mast 
cells and eosinophils express IP,R type 1 and type 2. IP,R type 
2 and type 3 are extensively expressed in thymocytes and sple- 
nocytes. 
3.3. Subcellular localization of IP,R subtypes in CA4K 
Our previous Northern blot analysis had shown that CMK 
cells expressed IP,Rs type 1 and type 2 [17]. The same expres- 
sion profile of IP,Rs were obtained by Western blot analysis 
(data not shown). CMK cells were stained with the monoclonal 
antibodies KM1 112 and KM1083, and observed under fluores- 
cence confocal microscopy (Fig. 6). Under the same conditions 
of staining and microscopic observation, KM1083 stained 
rather homogenously the cytoplasmic space with many strongly 
stained small domains (Fig. 6B), whilst KM 1112 stained inten- 
sively a few areas of the cytoplasm (Fig. 6A). Very interestingly, 
KM1083 stained positively the regions near the plasma mem- 
brane in a patchy manner. Even when the signals from the 
cytoplasm were roughly normalized (Fig. 6, insets), no staining 
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Fig. 5. Western blot analysis of IP,R subtypes in inflammatory cells. 
Macrophages (lane l), thymocytes (lane 2), splenocytes (lane 3), PMN 
(lane 4) and mast cells (lane 5) of rat, and eosinophils of guinea pig (lane 
6) were solubilized in the sample buffer and subjected to SDS-PAGE 
and Western blotting (50 pg protein/lane). IP,R subtypes were detected 
with the monoclonal antibody KM1 112 to IP,R type 1 (upper panels), 
KM1083 to type 2 (middle panels) and KM1082 to type 3 (bottom 
panels), respectively. Arrowheads indicate the position of IP,Rs. 
of the regions of plasma membrane was observed for KM1 112. 
These staining patterns were blocked by the immunizing pep- 
tide-1C and peptide-2C, respectively (data not shown). The 
result indicates that the subcellular localization of these two 
IP,R subtypes in CMK is different. 
4. Disctlssion 
Monoclonal antibodies are inevitably the tool for studying 
the structures, functions and tissue/subcellular localization of 
IP,Rs. In practice, using monoclonal antibodies against IP3R 
type 1, tissue and cellular localization, phosphorylation and 
tetramer formation of the IP,R subtype have been elucidated 
[2,3,18,271. It was shown by cDNA cloning, Northern blot and 
in situ hybridization analysis that there are at least three sub- 
types in the IP3R family and that these subtypes are differently 
expressed in tissues [1 l-161 and in many specific hematopoietic 
cells [17]. 
Using the synthetic peptides corresponding to the COOH- 
termini and the loops between the fifth and the sixth transmem- 
brane regions of human IP,R subtypes [13], we succeeded in 
establishing the hybridomas producing anti-IP,R type 1,2 and 
3 monoclonal antibodies with high specificity. Employing these 
antibodies, we revealed that IP3R type 2 and 3 are expressed 
in thymocytes. It has been reported that, though specific [31-IJIP3 
binding activities of thymus and Jurkat plasma membranes are 
similar, it is quite different from that of cerebellum, and that 
thymus IP,R protein possesses glycans of higher sialic acid 
content than cerebellum IP,R (IP,R type 1) [28]. We found that 
the possible N-glycosylation site of IP,R type 3 is different from 
that of IP,R type 1 and 2 with respect o the number of sites 
and the nearby amino acid sequences [ 131. Such differences may 
lead to different sugar contents among these IP,R subtypes. 
Thus, the previously characterized IP,R in thymus might be the 
IP,R type 3 detected in this study. It has been reported that 
IP3R of the T-lymphoma cell line forms complexes with cy- 
toskeletal proteins such as ankyrin well known to bind a mnn- 
ber of plasma membrane-associated proteins [29]. Thus, it is 
very interesting to examine IP,R subtypes associated with such 
cytoskeletal proteins with respect to the regulation of their 
channel activities in cytoskeleton-dependent manner. 
The expression profiles of IP,R subtypes protein were quite 
different among inflammatory cells tested. Interestingly, plural 
types of IP,R were expressed in the same cells simultaneously. 
These results agree with our previous report analyzing IP3R 
Fig. 6. Immunofluorescence staining of IP,R type 1 and 2 in CMK cells. Fixed and permeabilized CMK cells were immunostained with the monoclonal 
antibody KM1 112 to IP,R type 1 or KM1083 to IP,R type 2. FITC positive cells stained with KM1 112 (A) and KM1083 (B) were examined under 
fluorescence confocal microscopy. Insets show cells stained with KM1 112 and KM1083, respectively, with rough normalization of signals from their 
cytoplasmic regions. 
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subtype expression by Northern blot analysis [17]. Such cell- 
type specific expression of IP,R subtypes may be tightly related 
to specific cellular functions such as phagocytosis, secretion 
and chemotaxis. This finding also raises a question whether the 
Ca” channels formed by IPSR are homomeric or heteromeric 
tetramers [17]. Since our monoclonal antibodies imnumopre- 
cipitate each of the three IP,R subtypes, these antibodies will 
be a useful tool to analyze the subunit composition of the 
channels. 
Immunohistochemical studies using antibodies raised against 
type 1 protein or unidentified IP,R protein from a T cell line 
have revealed that IP,R localized also to plasma membrane 
[8,9] and perinuclear membrane [30,31]. To date, no data are 
available for cells expressing plural types of IP,R about the 
subcellular localization of each of these IP,R subtypes. Surpris- 
ingly, the immunocytochemical examination of CMK cells re- 
vealed that the subcellular localization is distinctively regulated 
for each of IP,Rs. Platelets are produced at the surface of 
megakaryocytes presumably being accompanied with the re- 
construction of cytoskeletons. The IP,R type 2 located near the 
plasma membrane may contribute to the process by releasing 
Ca*+ at appropriate times during the reconstruction. Im- 
munocytochemical observation by electron microscope using 
these monoclonal antibodies will give more detailed subcellular 
localization. 
The COOH-terminal regions of each IP,R subtype are well 
conserved among human, mouse and rat [lO--151. This study 
has shown that our monoclonal antibodies raised against the 
synthetic peptides corresponding to human IP,R subtypes react 
with the counterparts of rodent IP3R subtypes. Thus, our mon- 
oclonal antibodies have provided a route for the immunohisto- 
chemical and immunocytochemical study of the normal and 
human disease model-animals established in these species. Such 
studies are now in progress and will be reported. 
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